 Crinetics Pharmaceuticals, Inc. CRNX, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that over 50 of the patients enrolled in the ACROBAT Edge Phase 2 clinical trial have completed the study. Based on the results of the previously announced interim analysis, Crinetics believes that the data from Edge is supportive of moving forward into Phase 3. 